ESPERITE (ESP) : L1 Capital confirms its investment in Esperite and announces new funding for up to EUR 1.1 million before July 12, 2017
May 31, 2017 02:26 ET
|
Esperite N.V.
Zutphen, The Netherlands, 31 May 2017 As of today, EUR 940,000 out of the EUR 1.0 million tranche issued on March 8, 2017 have been converted into shares by European Select Growth Opportunities...
ESPERITE (ESP) Q1 consolidated revenue higher compared to budget
May 31, 2017 01:57 ET
|
Esperite N.V.
EBITDA improved compared to budget as a result of cost control Zutphen, the Netherlands - 31 May 2017 Market Update Q1 2017 The Q1 actual consolidated revenue of Esperite was higher compared to...
ESPERITE (ESP) has concluded new agreements with its note holders
May 31, 2017 01:17 ET
|
Esperite N.V.
Zutphen, the Netherlands - 31 May 2017 The unfortunate liquidation procedure against Genoma SA, ruled on May 4th 2017, for which an appeal is still pending, has triggered the obligation to repay...
ESPERITE N.V. convenes Annual General Meeting of Shareholders
May 23, 2017 09:43 ET
|
Esperite N.V.
Zutphen, The Netherlands - 23 May 2017 Esperite N.V. (Euronext: ESP, "Esperite") announces that it has convened its Annual General Meeting of Shareholders ("AGM") to be held on 4 July 2017 at...
ESPERITE (ESP) financial results for 2016 published
May 23, 2017 01:17 ET
|
Esperite N.V.
Zutphen, the Netherlands - 23 May 2017 ESPERITE N.V. (Euronext: ESP, "Esperite" or "the Group") has published today its Annual Report for the year ended 31 December 2016. The 2016 Annual Report...
Esperite further delays publication of 2016 Annual Report
May 20, 2017 12:28 ET
|
Esperite N.V.
Zutphen, The Netherlands - 20 May 2017 Esperite N.V. (Euronext: ESP, the "Company" or "Esperite") announces that additional time is needed for the Company to publish its Annual Report for the...
Esperite (ESP) announces that Genoma SA filed appeal to the decision ruled by the Swiss Court
May 19, 2017 07:19 ET
|
Esperite N.V.
Genoma has filed appeal to the decision of liquidation taken on May 4th 2017. Genoma considers this decision arbitrary due to the circumstances of the commercial and legal relationship with...
Esperite (ESP) confirme le développement positif de ses activités génétiques et annonce son intention de réclamer 5,2 millions de dommages-intérêts à Premaitha (NIPT)
May 15, 2017 04:17 ET
|
Esperite N.V.
Zutphen, les Pays-Bas, 15 mai 2017 La dernière action de Premaitha contre Genoma démontre sa tentative désespérée de cacher au public la situation financière de Premaitha. L'effet de leur action...
Esperite (ESP) - Esperite confirma el desarrollo positivo de sus actuales y futuras actividades en el mercado genético, y anuncia su intención de reclamar a Premaitha (NIPT) 5,2€M
May 15, 2017 04:17 ET
|
Esperite N.V.
Zutphen, Países Bajos, 15 mayo 2017 La última acción llevada a cabo por Premaitha contra Genoma demuestra una desesperada intención de encubrir la situación financiera de Premaitha. Los efectos de...
Esperite (ESP) - Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Million euro damages against Premaitha (NIPT)
May 15, 2017 04:17 ET
|
Esperite N.V.
Zutphen, The Netherlands, 15 May 2017 Premaitha's latest action against Genoma demonstrates its desperate attempt to conceal Premaitha's financial situation. The effect of their legal action...